<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>RSS for IMMUNOL RES</title><link>http://academic.research.microsoft.com/Rss.aspx?id=6645&amp;cata=6</link><description>Search RSS feed for Microsoft Academic Search</description><generator>MSRA Libra RSS Burner</generator><copyright>(c)2008 Microsoft Corpration, All right reserved.</copyright><pubDate>Mon, 20 May 2013 07:45:30 GMT</pubDate><lastBuildDate>Mon, 20 May 2013 07:45:30 GMT</lastBuildDate><category /><item><title>Biology and function of neuroimmune semaphorins 4A and 4D</title><link>http://academic.research.microsoft.com/Publication/48281435</link><pubDate>Mon, 20 May 2013 07:45:30 GMT</pubDate><guid isPermaLink="false">48281435</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/48310029">EusebiusHenry Nkyimbeng-Takwi</a>, <a href="http://academic.research.microsoft.com/Author/38741915">Svetlana P. Chapoval</a><span style="margin-left:20px">(Citations:3)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/t1456q71185vh840">view publication</a></span></p><p>Semaphorins belong to a family of membrane-bound and secreted molecules that regulate the functional activity of axons in the nervous system. Sema4A and Sema4D were the first semaphorins also found to be expressed in immune cells and were, therefore, termed “immune semaphorins”. It is known that Sema4A has three functional receptors, namely Plexin D1, Plexin B1, and Tim-2, ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 1, pp. 10-21, 2011</cite>]]></description></item><item><title>IL17 signaling in host defense against Candida albicans</title><link>http://academic.research.microsoft.com/Publication/48802922</link><pubDate>Mon, 20 May 2013 07:45:29 GMT</pubDate><guid isPermaLink="false">48802922</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23770074">Sarah L. Gaffen</a>, <a href="http://academic.research.microsoft.com/Author/27321573">Nydiaris Hernández-Santos</a>, <a href="http://academic.research.microsoft.com/Author/47618794">Alanna C. Peterson</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/97221q31v872519j.pdf">view publication</a></span></p><p>The discovery of the Th17 lineage in 2005 triggered a major change in how immunity to infectious diseases is viewed. Fungal infections, in particular, have long been a relatively understudied area of investigation in terms of the host immune response. Candida albicans is a commensal yeast that colonizes mucosal sites and skin. In healthy individuals, it is non-pathogenic, but ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 181-187, 2011</cite>]]></description></item><item><title>T cell recognition of weak ligands: roles of signaling, receptor number, and affinity</title><link>http://academic.research.microsoft.com/Publication/47837393</link><pubDate>Mon, 20 May 2013 07:45:28 GMT</pubDate><guid isPermaLink="false">47837393</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/37631486">Lindsay J. Edwards</a>, <a href="http://academic.research.microsoft.com/Author/23144564">Brian D. Evavold</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/q3425q504786m2n4.pdf">view publication</a></span></p><p>T cell recognition of antigen is a crucial aspect of the adaptive immune response. One of the most common means of pathogen immune evasion is mutation of T cell epitopes. T cell recognition of such ligands can result in a variety of outcomes including activation, apoptosis and anergy. The ability of a given T cell to respond to a specific ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 1, pp. 39-48, 2011</cite>]]></description></item><item><title>Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development</title><link>http://academic.research.microsoft.com/Publication/47897847</link><pubDate>Mon, 20 May 2013 07:45:27 GMT</pubDate><guid isPermaLink="false">47897847</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/5398845">Eva Chung</a>, <a href="http://academic.research.microsoft.com/Author/55545846">Motonari Kondo</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/tm76553964877781">view publication</a></span></p><p>Recent research on hematological malignancies has shown that malignant cells often co-opt physiological pathways to promote their growth and development. Bone marrow homeostasis requires a fine balance between cellular differentiation and self-renewal; cell survival and apoptosis; and cellular proliferation and senescence. The Ras/Raf/MEK/ERK pathway has been shown to be important in regulating these biological functions. ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 248-268, 2011</cite>]]></description></item><item><title>Macrophage responses to bacterial toxins: a balance between activation and suppression</title><link>http://academic.research.microsoft.com/Publication/48800066</link><pubDate>Mon, 20 May 2013 07:45:26 GMT</pubDate><guid isPermaLink="false">48800066</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/5255889">Peter A. Keyel</a>, <a href="http://academic.research.microsoft.com/Author/46601233">Michelle E. Heid</a>, <a href="http://academic.research.microsoft.com/Author/23853471">Russell D. Salter</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/730228684n612107">view publication</a></span></p><p>Toxins secreted by bacteria can impact the host in a number of different ways. In some infections, toxins play a crucial and central role in pathogenesis (i.e., anthrax), while in other bacterial infections, the role of toxins is less understood. The cholesterol-dependent cytolysins (CDCs), of which streptolysin O is a prototype, are a class of pore-forming toxins ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 118-123, 2011</cite>]]></description></item><item><title>Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity</title><link>http://academic.research.microsoft.com/Publication/48856337</link><pubDate>Mon, 20 May 2013 07:45:25 GMT</pubDate><guid isPermaLink="false">48856337</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/21153286">Steve C. Lee</a>, <a href="http://academic.research.microsoft.com/Author/9249279">Raghvendra M. Srivastava</a>, <a href="http://academic.research.microsoft.com/Author/4832088">Andrés López-Albaitero</a>, <a href="http://academic.research.microsoft.com/Author/21419373">Soldano Ferrone</a>, <a href="http://academic.research.microsoft.com/Author/11973347">Robert L. Ferris</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/v08286011226241w.pdf">view publication</a></span></p><p>Tumor antigen (TA)-targeted monoclonal antibodies (mAb), trastuzumab, cetuximab, panitumumab, and rituximab, have been among the most successful new therapies in the present generation. Clinical activity is observed as a single agent, or in combination with radiotherapy or chemotherapy, against metastatic colorectal cancer, head and neck cancer, breast cancer, and follicular lymphoma. However, the activity is seen only in a ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 248-254, 2011</cite>]]></description></item><item><title>Stage-specific functions of E-proteins at the β-selection and T-cell receptor checkpoints during thymocyte development</title><link>http://academic.research.microsoft.com/Publication/48289742</link><pubDate>Mon, 20 May 2013 07:45:24 GMT</pubDate><guid isPermaLink="false">48289742</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/53648708">Mary Elizabeth Jones</a>, <a href="http://academic.research.microsoft.com/Author/53661045">Yuan Zhuang</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/t5k127402p432711.pdf">view publication</a></span></p><p>The E-protein transcription factors E2A and HEB function in a lineage- and stage-specific manner to orchestrate many critical events throughout lymphocyte development. The function of E-proteins in both B- and T-lymphocyte development has been extensively studied through the use of single-gene knockout animals. Unlike B cells, which rely primarily on E2A alone, T cells are ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 202-215, 2011</cite>]]></description></item><item><title>Intracellular osteopontin (iOPN) and immunity</title><link>http://academic.research.microsoft.com/Publication/47994892</link><pubDate>Mon, 20 May 2013 07:45:23 GMT</pubDate><guid isPermaLink="false">47994892</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/47261260">Makoto Inoue</a>, <a href="http://academic.research.microsoft.com/Author/24032006">Mari L. Shinohara</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/y168jq8832r2j053">view publication</a></span></p><p>Osteopontin (OPN) is a protein involved in various pathophysiological events. OPN has been studied as a secreted protein, but recent reports showed that OPN can be found in the cytoplasm and the nucleus. Therefore, some OPN molecules are not secreted and stay in cells. Such intracellular OPN (iOPN) has biological functions distinct from secreted OPN (sOPN). iOPN is involved in ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 160-172, 2011</cite>]]></description></item><item><title>The role of natural regulatory T cells in infection</title><link>http://academic.research.microsoft.com/Publication/48014695</link><pubDate>Mon, 20 May 2013 07:45:22 GMT</pubDate><guid isPermaLink="false">48014695</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/37915680">Ana M. Sanchez</a>, <a href="http://academic.research.microsoft.com/Author/3382803">Yiping Yang</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/37141k4g33175367">view publication</a></span></p><p>Naturally occurring regulatory T cells (TReg) suppress multiple cell types of the immune system to maintain dominant tolerance to protect from autoimmunity, down-modulate anti-tumor immunity and restrain allergic diseases. In addition to these functions, TReg can alter effector responses to invading pathogens, leading to a variety of outcomes affecting both the host and infecting microorganisms. Here, we review ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 124-134, 2011</cite>]]></description></item><item><title>Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response</title><link>http://academic.research.microsoft.com/Publication/47625662</link><pubDate>Mon, 20 May 2013 07:45:21 GMT</pubDate><guid isPermaLink="false">47625662</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/24952128">Mike Kulis</a>, <a href="http://academic.research.microsoft.com/Author/53644308">Brian P. Vickery</a>, <a href="http://academic.research.microsoft.com/Author/21210413">A. Wesley Burks</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/b3n8749k40801692">view publication</a></span></p><p>There is no approved therapy for food allergies, which affect 12 million people in the United States and millions more worldwide. In the last few years, our research team at Duke has begun to develop protocols to treat peanut and other food allergies. Two distinct therapies are being developed. Oral immunotherapy (OIT), which relies on ingestion of increasing amounts of the ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 216-226, 2011</cite>]]></description></item><item><title>Lung myeloid-derived suppressor cells and regulation of inflammation</title><link>http://academic.research.microsoft.com/Publication/48822003</link><pubDate>Mon, 20 May 2013 07:45:20 GMT</pubDate><guid isPermaLink="false">48822003</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23773202">Prabir Ray</a>, <a href="http://academic.research.microsoft.com/Author/26701507">Meenakshi Arora</a>, <a href="http://academic.research.microsoft.com/Author/35870544">Stephanie L. Poe</a>, <a href="http://academic.research.microsoft.com/Author/53604633">Anuradha Ray</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/jwkg7m621u70tg07">view publication</a></span></p><p>Myeloid-derived suppressor cells (MDSCs) have been investigated largely in the context of tumor progression. In contrast to the negative connotation of MDSCs in cancer immunity, our laboratory has recently reported on the development and role of pulmonary MDSC-like cells (CD11b+Gr1intF4/80+) in the regulation of allergic airway inflammation. These regulatory cells were expanded in a TLR4/MyD88-dependent ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 153-158, 2011</cite>]]></description></item><item><title>AID expression during B-cell development: searching for answers</title><link>http://academic.research.microsoft.com/Publication/47591036</link><pubDate>Mon, 20 May 2013 07:45:19 GMT</pubDate><guid isPermaLink="false">47591036</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/25516640">Masayuki Kuraoka</a>, <a href="http://academic.research.microsoft.com/Author/48499833">Laurie McWilliams</a>, <a href="http://academic.research.microsoft.com/Author/23393620">Garnett Kelsoe</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/0682773t24227240.pdf">view publication</a></span></p><p>Expression of activation-induced cytidine deaminase (AID) by germinal center (GC) B cells drives the processes of immunoglobulin (Ig) somatic hypermutation (SHM) and class switch recombination (CSR) necessary for the generation of high affinity IgG serum antibody and the memory B-cell compartment. Increasing evidence indicates that AID is also expressed at low levels in developing B cells but to ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 3-13, 2011</cite>]]></description></item><item><title>B-lymphocyte effector functions in health and disease</title><link>http://academic.research.microsoft.com/Publication/47633996</link><pubDate>Mon, 20 May 2013 07:45:18 GMT</pubDate><guid isPermaLink="false">47633996</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/48241461">David J. DiLilloMayuka</a>, <a href="http://academic.research.microsoft.com/Author/53329419">Mayuka Horikawa</a>, <a href="http://academic.research.microsoft.com/Author/10728882">Thomas F. Tedder</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/e08444035u6654j5">view publication</a></span></p><p>B-lymphocytes have traditionally been thought to contribute to immunity and autoimmune disease through terminal differentiation into plasma cells that secrete antibody. However, studies in mice and recent clinical studies have demonstrated that genetically altered B-cell function and B-cell-targeted therapies can significantly affect autoimmune diseases that were predominantly thought to be T-cell-mediated. B-cell depletion ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 281-292, 2011</cite>]]></description></item><item><title>Microparticles as a source of extracellular DNA</title><link>http://academic.research.microsoft.com/Publication/47613785</link><pubDate>Mon, 20 May 2013 07:45:17 GMT</pubDate><guid isPermaLink="false">47613785</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23557242">David S. Pisetsky</a>, <a href="http://academic.research.microsoft.com/Author/27631256">Julie Gauley</a>, <a href="http://academic.research.microsoft.com/Author/21308502">Anirudh J. Ullal</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/764772wu1m967335">view publication</a></span></p><p>Microparticles are small membrane-bound vesicles that display pro-inflammatory and pro-thrombotic activities important in the pathogenesis of a wide variety of diseases. These particles are released from activated and dying cells and incorporate nuclear and cytoplasmic molecules for extracellular export. Of these molecules, DNA is a central autoantigen in systemic lupus erythematosus (SLE). As studies in our laboratory ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 227-234, 2011</cite>]]></description></item><item><title>CD8 + T cells in systemic sclerosis</title><link>http://academic.research.microsoft.com/Publication/48806932</link><pubDate>Mon, 20 May 2013 07:45:16 GMT</pubDate><guid isPermaLink="false">48806932</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/26070094">Patrizia Fuschiotti</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/d010426427k74x5w">view publication</a></span></p><p>Systemic sclerosis (SSc) is a progressive and highly debilitating autoimmune disorder characterized by inflammation, fibrosis, and vascular damage of the connective tissue. T cell-derived cytokines have been implicated in the induction of fibrosis. We found that high levels of the profibrotic type-2 cytokine IL-13 are produced by peripheral blood effector CD8+ T cells from SSc patients compared ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 188-194, 2011</cite>]]></description></item><item><title>Transcriptional regulation by STAT6</title><link>http://academic.research.microsoft.com/Publication/47593172</link><pubDate>Mon, 20 May 2013 07:45:15 GMT</pubDate><guid isPermaLink="false">47593172</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/25562143">Shreevrat Goenka</a>, <a href="http://academic.research.microsoft.com/Author/23728086">Mark H. Kaplan</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/12638m117566w573">view publication</a></span></p><p>Signal transducer and activator of transcription (STAT) proteins are critical mediators of cytokine signaling. Among the seven STAT proteins, STAT6 is activated by IL-4 and IL-13 and plays a predominant role in the immune system. However, there is increasing evidence that STAT6 may function in other tissues and organ systems. IL-4, IL-13, and STAT6 promote humoral ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 1, pp. 87-96, 2011</cite>]]></description></item><item><title>Immunological alterations mediated by adenosine during host-microbial interactions</title><link>http://academic.research.microsoft.com/Publication/48048653</link><pubDate>Mon, 20 May 2013 07:45:14 GMT</pubDate><guid isPermaLink="false">48048653</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/46886817">Ioannis DrygiannakisPeter</a>, <a href="http://academic.research.microsoft.com/Author/53586490">Peter B. Ernst</a>, <a href="http://academic.research.microsoft.com/Author/2199602">David Lowe</a>, <a href="http://academic.research.microsoft.com/Author/39473812">Ian J. Glomski</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/al87tl3l36767j32.pdf">view publication</a></span></p><p>Adenosine accumulates in inflammation and ischemia but it is more than an end-product of ATP catabolism. Signaling through different receptors with distinct, cell-specific cytoplasmic pathways, adenosine is now recognized as an inducible switch that regulates the immune system. By acting through the A2AAR, adenosine shapes T cell function, largely by conferring an anti-inflammatory tone on effector Th ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 1, pp. 69-77, 2011</cite>]]></description></item><item><title>A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice</title><link>http://academic.research.microsoft.com/Publication/48863028</link><pubDate>Mon, 20 May 2013 07:45:13 GMT</pubDate><guid isPermaLink="false">48863028</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/55203082">Ming S. Lin</a>, <a href="http://academic.research.microsoft.com/Author/10477825">Hubert M. Tse</a>, <a href="http://academic.research.microsoft.com/Author/52360108">Meghan M. Delmastro</a>, <a href="http://academic.research.microsoft.com/Author/12387719">Suzanne Bertera</a>, <a href="http://academic.research.microsoft.com/Author/55872766">Caterina T. Wong</a>, <a href="http://academic.research.microsoft.com/Author/29287992">Robert Lakomy</a>, <a href="http://academic.research.microsoft.com/Author/56882832">Jing He</a>, <a href="http://academic.research.microsoft.com/Author/25082371">Martha M. Sklavos</a>, <a href="http://academic.research.microsoft.com/Author/45590139">Gina M. Coudriet</a>, <a href="http://academic.research.microsoft.com/Author/10862443">Massimo Pietropaolo</a>, <a href="http://academic.research.microsoft.com/Author/12327983">Massimo M. Trucco</a>, <a href="http://academic.research.microsoft.com/Author/23746834">Jon D. Piganelli</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/wp557124084017g1.pdf">view publication</a></span></p><p>Previous studies by our group, using an experimental autoimmune thyroiditis (EAT) model in Strain 13 inbred guinea pigs, resulted in T cell-mediated delayed hypersensitivity; however, autoantibodies proved not to be cytotoxic to thyroid epithelial cells in the presence or absence of complement proteins. Albeit, T cell-mediated lymphocyte cytotoxicity began to diminish sharply concomitantly with increasing titers of circulating ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 213-220, 2011</cite>]]></description></item><item><title>Receptor signaling in immune cell development and function</title><link>http://academic.research.microsoft.com/Publication/48020958</link><pubDate>Mon, 20 May 2013 07:45:12 GMT</pubDate><guid isPermaLink="false">48020958</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23746113">Xiao-Ping Zhong</a>, <a href="http://academic.research.microsoft.com/Author/23772134">Jinwook Shin</a>, <a href="http://academic.research.microsoft.com/Author/27853548">Balachandra K. Gorentla</a>, <a href="http://academic.research.microsoft.com/Author/11535100">Tommy O’Brien</a>, <a href="http://academic.research.microsoft.com/Author/45473949">Sruti Srivatsan</a>, <a href="http://academic.research.microsoft.com/Author/47258631">Li Xu</a>, <a href="http://academic.research.microsoft.com/Author/48641746">Yong Chen</a>, <a href="http://academic.research.microsoft.com/Author/43774605">Danli Xie</a>, <a href="http://academic.research.microsoft.com/Author/23673869">Hongjie Pan</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/4w5490q7v70k3881">view publication</a></span></p><p>Immune cell development and function must be tightly regulated through cell surface receptors to ensure proper responses to pathogen and tolerance to self. In T cells, the signal from the T-cell receptor is essential for T-cell maturation, homeostasis, and activation. In mast cells, the high-affinity receptor for IgE transduces signal that promotes mast cell survival and induces ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 109-123, 2011</cite>]]></description></item><item><title>Transcriptional and epigenetic regulation of B cell development</title><link>http://academic.research.microsoft.com/Publication/48865355</link><pubDate>Mon, 20 May 2013 07:45:11 GMT</pubDate><guid isPermaLink="false">48865355</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/53516377">Patricia SantosFortuna</a>, <a href="http://academic.research.microsoft.com/Author/56040553">Fortuna Arumemi</a>, <a href="http://academic.research.microsoft.com/Author/3528572">Kyung Soo Park</a>, <a href="http://academic.research.microsoft.com/Author/23530015">Lisa Borghesi</a>, <a href="http://academic.research.microsoft.com/Author/23668394">Christine Milcarek</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/x5762p531ku7l367.pdf">view publication</a></span></p><p>B cell development starts in the bone marrow where hematopoietic stem cells (HSCs) progress through sequential developmental stages, as it differentiates into a naïve B cell expressing surface immunoglobulin. In the periphery, B cells that encounter antigen can further differentiate into antibody-secreting plasma cells. In this review, we focus on two factors, E47 and ELL2, which play important roles...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 105-112, 2011</cite>]]></description></item><item><title>A tale of two TRAPs: LAT and LAB in the regulation of lymphocyte development, activation, and autoimmunity</title><link>http://academic.research.microsoft.com/Publication/48065915</link><pubDate>Mon, 20 May 2013 07:45:10 GMT</pubDate><guid isPermaLink="false">48065915</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/48108146">Deirdre M. FullerMinghua</a>, <a href="http://academic.research.microsoft.com/Author/36979553">Minghua Zhu</a>, <a href="http://academic.research.microsoft.com/Author/23981976">Chih-Wen Ou-Yang</a>, <a href="http://academic.research.microsoft.com/Author/9370514">Sarah A. Sullivan</a>, <a href="http://academic.research.microsoft.com/Author/37080760">Weiguo Zhang</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/el365m41j2qk815k.pdf">view publication</a></span></p><p>Transmembrane adaptor proteins (TRAPs) link antigen receptor engagement to downstream cellular processes. Although these proteins typically lack intrinsic enzymatic activity, they are phosphorylated on multiple tyrosine residues following lymphocyte activation, allowing them to function as scaffolds for the assembly of multi-molecular signaling complexes. Among the many TRAPs that have been discovered in recent years, the LAT (linker for activation ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 97-108, 2011</cite>]]></description></item><item><title>Ambient ozone and pulmonary innate immunity</title><link>http://academic.research.microsoft.com/Publication/47609870</link><pubDate>Mon, 20 May 2013 07:45:09 GMT</pubDate><guid isPermaLink="false">47609870</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/27477832">Mashael Al-Hegelan</a>, <a href="http://academic.research.microsoft.com/Author/41836095">Robert M. Tighe</a>, <a href="http://academic.research.microsoft.com/Author/47236953">Christian Castillo</a>, <a href="http://academic.research.microsoft.com/Author/23562976">John W. Hollingsworth</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/655887v0806930tp">view publication</a></span></p><p>Ambient ozone is a criteria air pollutant that impacts both human morbidity and mortality. The effect of ozone inhalation includes both toxicity to lung tissue and alteration of the host immunologic response. The innate immune system facilitates immediate recognition of both foreign pathogens and tissue damage. Emerging evidence supports that ozone can modify the host innate immune response and that ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 173-191, 2011</cite>]]></description></item><item><title>A role for the heat shock protein–CD91 axis in the initiation of immune responses to tumors</title><link>http://academic.research.microsoft.com/Publication/48808792</link><pubDate>Mon, 20 May 2013 07:45:08 GMT</pubDate><guid isPermaLink="false">48808792</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/37209267">Sudesh Pawaria</a>, <a href="http://academic.research.microsoft.com/Author/28029918">Michelle Nicole Messmer</a>, <a href="http://academic.research.microsoft.com/Author/43152258">Yu Jerry Zhou</a>, <a href="http://academic.research.microsoft.com/Author/23678318">Robert Julian Binder</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/e6277145l15660j3">view publication</a></span></p><p>For over 100 years, it has been established that tumor-specific immune responses can frequently be detected in the tumor-bearing host. Whether or not these immune responses are capable of controlling the growth of the tumor is influenced by many factors. However, the mechanism by which the immune responses are initiated in the first place has remained a dilemma. In ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 255-260, 2011</cite>]]></description></item><item><title>Tonsillar CD4 + FOXP3 + T-regulatory cell dynamics in primary EBV infection</title><link>http://academic.research.microsoft.com/Publication/48349532</link><pubDate>Mon, 20 May 2013 07:45:07 GMT</pubDate><guid isPermaLink="false">48349532</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/47679708">Yen-Hung ChowHsuen-Wen Chang</a>, <a href="http://academic.research.microsoft.com/Author/53661239">Hsuen-Wen Chang</a>, <a href="http://academic.research.microsoft.com/Author/42621071">Raymond Sia</a>, <a href="http://academic.research.microsoft.com/Author/54310419">Pele Chong</a>, <a href="http://academic.research.microsoft.com/Author/27517826">Charles Sia</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/w5347kxl2451v741.pdf">view publication</a></span></p><p>CD8+ lymphocytosis is recognized as the primary immunopathological response generated in primary EBV infection that may manifest itself as a benign lymphoproliferative disorder, infectious mononucleosis (IM). While CD4+FOXP3+ T-regulatory cells (Treg cells) are well accepted to inhibit T-cell responses, it is puzzling why massive expansion of CD8+ lymphocytes still occurs despite CD4+FOXP3+ Treg cells are localized in tonsils, ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 1, pp. 97-101, 2011</cite>]]></description></item><item><title>Importance of MUC1 and spontaneous mouse tumor models for understanding the immunobiology of human adenocarcinomas</title><link>http://academic.research.microsoft.com/Publication/48809875</link><pubDate>Mon, 20 May 2013 07:45:06 GMT</pubDate><guid isPermaLink="false">48809875</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23680587">Olivera J. Finn</a>, <a href="http://academic.research.microsoft.com/Author/5073629">Kira R. Gantt</a>, <a href="http://academic.research.microsoft.com/Author/23731427">Andrew J. Lepisto</a>, <a href="http://academic.research.microsoft.com/Author/26104157">Sharmila Pejawar-Gaddy</a>, <a href="http://academic.research.microsoft.com/Author/50527101">Jia Xue</a>, <a href="http://academic.research.microsoft.com/Author/26230729">Pamela L. Beatty</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/f52v534l28728214">view publication</a></span></p><p>Many important aspects of cancer biology, such as cancer initiation, progression, and metastasis, have been studied in animal models, mostly mice. As long as cancer was considered primarily a genetic disease, the study of transplantable mouse tumors, or even human tumor xenografts in immunocompromised mice, appeared to suffice. Many important genetic events that lead to transformation and in vivo tumor ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 261-268, 2011</cite>]]></description></item><item><title>Latent tuberculosis: what the host “sees”?</title><link>http://academic.research.microsoft.com/Publication/48793547</link><pubDate>Mon, 20 May 2013 07:45:05 GMT</pubDate><guid isPermaLink="false">48793547</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/48490078">Hannah P. GideonJoAnne</a>, <a href="http://academic.research.microsoft.com/Author/3156092">JoAnne L. Flynn</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/2334323273374w17.pdf">view publication</a></span></p><p>Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB), is the most successful pathogen of mankind and remains a major threat to global health as the leading cause of death due to a bacterial pathogen. Yet 90–95% of those who are infected with MTB remain otherwise healthy. These people are classified as “latently infected,” but remain a reservoir ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 202-212, 2011</cite>]]></description></item><item><title>AID: a riddle wrapped in a mystery inside an enigma</title><link>http://academic.research.microsoft.com/Publication/48008506</link><pubDate>Mon, 20 May 2013 07:45:04 GMT</pubDate><guid isPermaLink="false">48008506</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/28157633">Dana C. Upton</a>, <a href="http://academic.research.microsoft.com/Author/56502865">Briana L. Gregory</a>, <a href="http://academic.research.microsoft.com/Author/27701294">Rahul Arya</a>, <a href="http://academic.research.microsoft.com/Author/4450510">Shyam Unniraman</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/22m32r117u571731">view publication</a></span></p><p>To combat the ever-changing pool of pathogens we face, B cells generate highly optimized antibodies in two distinct steps. A large variety of antibodies are first generated randomly by V(D)J recombination, and then, upon encountering an antigen, antibodies are fine-tuned by somatic hypermutation and class switch recombination—both of which are initiated by the same protein, ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 14-24, 2011</cite>]]></description></item><item><title>Hepatic antigen-presenting cells and regulation of liver transplant outcome</title><link>http://academic.research.microsoft.com/Publication/48803836</link><pubDate>Mon, 20 May 2013 07:45:03 GMT</pubDate><guid isPermaLink="false">48803836</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/49577797">Angus W. ThomsonDavid</a>, <a href="http://academic.research.microsoft.com/Author/18300123">David A. Geller</a>, <a href="http://academic.research.microsoft.com/Author/38235641">Chandrashekhar Gandhi</a>, <a href="http://academic.research.microsoft.com/Author/22907164">Noriko Murase</a>, <a href="http://academic.research.microsoft.com/Author/23848257">A. Jake Demetris</a>, <a href="http://academic.research.microsoft.com/Author/4821045">Donna Beer-Stolz</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/a40722w362q7juu1.pdf">view publication</a></span></p><p>In the steady state, hepatic antigen (Ag)-presenting cells (APC) generally dampen systemic inflammatory responses to gut-derived Ags. Our studies focus on the role of specific liver APC populations, both non-parenchymal cells (dendritic cells [DC], Kupffer cells, and hepatic stellate cells [HSC]) and parenchymal cells, in the molecular regulation of tissue damage (ischemia and reperfusion [I/R] injury) ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 221-227, 2011</cite>]]></description></item><item><title>The long and the short of telomeres in bone marrow recipient SCID patients</title><link>http://academic.research.microsoft.com/Publication/47605056</link><pubDate>Mon, 20 May 2013 07:45:02 GMT</pubDate><guid isPermaLink="false">47605056</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/53626871">Marcella Sarzotti-KelsoeXiaoju</a>, <a href="http://academic.research.microsoft.com/Author/23543095">Xiaoju G. Daniell</a>, <a href="http://academic.research.microsoft.com/Author/23506168">John F. Whitesides</a>, <a href="http://academic.research.microsoft.com/Author/52287143">Rebecca H. Buckley</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/4w2kq528156jw85h.pdf">view publication</a></span></p><p>Telomeres are noncoding DNA regions at the end of the chromosomes that are crucial for genome stability. Since telomere length decreases with cell division, they can be used as a signature of cell proliferation history. T-cell reconstitution in severe combined immunodeficiency (SCID) subjects, recipients of T-cell-depleted, allogeneic-related bone marrow cells, is due to the development and ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 44-48, 2011</cite>]]></description></item><item><title>Dendritic cells and the maintenance of self-tolerance</title><link>http://academic.research.microsoft.com/Publication/48795625</link><pubDate>Mon, 20 May 2013 07:45:01 GMT</pubDate><guid isPermaLink="false">48795625</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/47953093">Penelope A. MorelMichael</a>, <a href="http://academic.research.microsoft.com/Author/2470089">Michael S. Turner</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/3q76577038361075.pdf">view publication</a></span></p><p>Dendritic cells (DC) play important roles in the initiation of immune responses and in the maintenance of self-tolerance. We have been studying the role of DC in the pathogenesis of type 1 diabetes and exploring the ability of specific DC subsets to prevent diabetes in non-obese diabetic (NOD) mice. DC presenting low doses of antigen are capable of ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 124-129, 2011</cite>]]></description></item><item><title>Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines</title><link>http://academic.research.microsoft.com/Publication/47982456</link><pubDate>Mon, 20 May 2013 07:45:00 GMT</pubDate><guid isPermaLink="false">47982456</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23551676">Timothy M. Clay</a>, <a href="http://academic.research.microsoft.com/Author/23701101">Takuya Osada</a>, <a href="http://academic.research.microsoft.com/Author/5714575">Zachary C. Hartman</a>, <a href="http://academic.research.microsoft.com/Author/23747883">Amy Hobeika</a>, <a href="http://academic.research.microsoft.com/Author/23579125">Gayathri Devi</a>, <a href="http://academic.research.microsoft.com/Author/10829674">Michael A. Morse</a>, <a href="http://academic.research.microsoft.com/Author/12362898">H. Kim Lyerly</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/x550837016330tn5.pdf">view publication</a></span></p><p>Aberrant signaling pathways are a hallmark of cancer. A variety of strategies for inhibiting signaling pathways have been developed, but monoclonal antibodies against receptor tyrosine kinases have been among the most successful. A challenge for these therapies is therapeutic unresponsiveness and acquired resistance due to mutations in the receptors, upregulation of alternate growth and survival pathways, or inadequate function of ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 235-247, 2011</cite>]]></description></item><item><title>Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?</title><link>http://academic.research.microsoft.com/Publication/48798312</link><pubDate>Mon, 20 May 2013 07:44:59 GMT</pubDate><guid isPermaLink="false">48798312</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23563181">Pawel Kalinski</a>, <a href="http://academic.research.microsoft.com/Author/24624602">Howard Edington</a>, <a href="http://academic.research.microsoft.com/Author/18177853">Herbert J. Zeh</a>, <a href="http://academic.research.microsoft.com/Author/23850420">Hideho Okada</a>, <a href="http://academic.research.microsoft.com/Author/24069996">Lisa H. Butterfield</a>, <a href="http://academic.research.microsoft.com/Author/23601104">John M. Kirkwood</a>, <a href="http://academic.research.microsoft.com/Author/23731186">David L. Bartlett</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/5t31417811024564.pdf">view publication</a></span></p><p>Dendritic cells (DCs) are the most powerful immunostimulatory cells specialized in the induction and regulation of immune responses. Their properties and the feasibility of their large-scale ex vivo generation led to the application of ex vivo-educated DCs to bypass the dysfunction of endogenous DCs in cancer patients and to induce therapeutic anti-cancer immunity. While multiple paradigms of ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 235-247, 2011</cite>]]></description></item><item><title>Immunologic aspects of monoclonal B-cell lymphocytosis</title><link>http://academic.research.microsoft.com/Publication/47636549</link><pubDate>Mon, 20 May 2013 07:44:58 GMT</pubDate><guid isPermaLink="false">47636549</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/47811386">Mark C. LanasaJ</a>, <a href="http://academic.research.microsoft.com/Author/53634556">J. Brice Weinberg</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/et576l707j107651">view publication</a></span></p><p>Monoclonal B-cell lymphocytosis (MBL) is a preclinical hematologic condition wherein small numbers of clonal B cells can be detected in the blood of otherwise healthy individuals. Most MBL have a surface immunophenotype nearly identical to that of chronic lymphocytic leukemia (CLL), though other phenotypes can also be identified. MBL has been shown to be a precursor state for CLL, ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 269-280, 2011</cite>]]></description></item><item><title>Erratum to: Mechanisms by which HIV envelope minimizes immunogenicity</title><link>http://academic.research.microsoft.com/Publication/47691332</link><pubDate>Mon, 20 May 2013 07:44:57 GMT</pubDate><guid isPermaLink="false">47691332</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/53802675">Haixiang Jiang</a>, <a href="http://academic.research.microsoft.com/Author/54656367">C. Garren Hester</a>, <a href="http://academic.research.microsoft.com/Author/11205723">Larry Liao</a>, <a href="http://academic.research.microsoft.com/Author/3220030">David C. Montefiori</a>, <a href="http://academic.research.microsoft.com/Author/23729333">Michael M. Frank</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/j1u610t6881p6544.pdf">view publication</a></span></p><p /><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 159-159, 2011</cite>]]></description></item><item><title>microRNAs at the regulatory frontier: an investigation into how microRNAs impact the development and effector functions of CD4 T cells</title><link>http://academic.research.microsoft.com/Publication/48147019</link><pubDate>Mon, 20 May 2013 07:44:56 GMT</pubDate><guid isPermaLink="false">48147019</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/46411491">Erik Allen Lykken</a>, <a href="http://academic.research.microsoft.com/Author/12502411">Qi-Jing Li</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/k6r2r53442325374">view publication</a></span></p><p>CD4 T cells are an integral part of adaptive immunity. microRNAs have been identified as fundamental regulators of post-transcriptional programs and to play roles in T lymphocytes’ development, differentiation, and effector functions. To better understand the role of miRNAs in T cells and to identify potential therapeutic tools and targets, we have undertaken studies of miRNAs that modulate or ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 87-96, 2011</cite>]]></description></item><item><title>Transcriptional control mechanisms associated with the nucleotide receptor P2X7, a critical regulator of immunologic, osteogenic, and neurologic functions</title><link>http://academic.research.microsoft.com/Publication/47698933</link><pubDate>Mon, 20 May 2013 07:44:55 GMT</pubDate><guid isPermaLink="false">47698933</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/27574068">Lisa Y. Lenertz</a>, <a href="http://academic.research.microsoft.com/Author/18194191">Monica L. Gavala</a>, <a href="http://academic.research.microsoft.com/Author/56410184">Yiming Zhu</a>, <a href="http://academic.research.microsoft.com/Author/36996568">Paul J. Bertics</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/j54867n474418752">view publication</a></span></p><p>The nucleotide receptor P2X7 is an attractive therapeutic target and potential biomarker for multiple inflammatory and neurologic disorders, and it is expressed in several immune, osteogenic, and neurologic cell types. Aside from its role in the nervous system, it is activated by ATP released at sites of tissue damage, inflammation, and infection. Ligand binding to P2X7 stimulates many cell responses, ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 1, pp. 22-38, 2011</cite>]]></description></item><item><title>T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract</title><link>http://academic.research.microsoft.com/Publication/48808032</link><pubDate>Mon, 20 May 2013 07:44:54 GMT</pubDate><guid isPermaLink="false">48808032</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23756461">Binfeng Lu</a>, <a href="http://academic.research.microsoft.com/Author/49209586">Lujun Chen</a>, <a href="http://academic.research.microsoft.com/Author/47495202">Lin Liu</a>, <a href="http://academic.research.microsoft.com/Author/53611634">Yibei Zhu</a>, <a href="http://academic.research.microsoft.com/Author/53679435">Changping Wu</a>, <a href="http://academic.research.microsoft.com/Author/53786739">Jingting Jiang</a>, <a href="http://academic.research.microsoft.com/Author/20117613">Xueguang Zhang</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/drq46260h215t7x2.pdf">view publication</a></span></p><p>Tumorigenesis can induce adaptive T-cell-mediated immune responses against malignant cells. Such cellular immune responses are actively suppressed by cancer cells via mechanisms of immune tolerance. We studied T-cell responses against tumor growth by examining tumor-infiltrating lymphocytes (TILs) in upper gastrointestinal (GI) cancers. The number of T-bet+ TILs correlates with better survival of esophageal cancer patients. ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 269-275, 2011</cite>]]></description></item><item><title>The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells</title><link>http://academic.research.microsoft.com/Publication/48856728</link><pubDate>Mon, 20 May 2013 07:44:53 GMT</pubDate><guid isPermaLink="false">48856728</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23911259">Ling Yu</a>, <a href="http://academic.research.microsoft.com/Author/24653047">Elvira Favoino</a>, <a href="http://academic.research.microsoft.com/Author/53824406">Yangyang Wang</a>, <a href="http://academic.research.microsoft.com/Author/11090141">Yang Ma</a>, <a href="http://academic.research.microsoft.com/Author/27755401">Xiaojuan Deng</a>, <a href="http://academic.research.microsoft.com/Author/24010665">Xinhui Wang</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/v1n422273310m612">view publication</a></span></p><p>PLX4032 is a BRAF-selective inhibitor shown to be efficacious in the treatment of melanomas presenting with the BRAFV600E mutation. However, favorable responses to treatment are short-lived, and complete remission is rarely observed. Therefore, it is important to identify novel therapies designed to enhance treatment responses and to increase the longevity of initial response to BRAF inhibitors. To this ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 294-302, 2011</cite>]]></description></item><item><title>Dissecting the role of dendritic cells in simian immunodeficiency virus infection and AIDS</title><link>http://academic.research.microsoft.com/Publication/48843744</link><pubDate>Mon, 20 May 2013 07:44:52 GMT</pubDate><guid isPermaLink="false">48843744</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/4159569">Elizabeth R. Wonderlich</a>, <a href="http://academic.research.microsoft.com/Author/37198896">Muhamuda Kader</a>, <a href="http://academic.research.microsoft.com/Author/25817084">Viskam Wijewardana</a>, <a href="http://academic.research.microsoft.com/Author/23675918">Simon M. Barratt-Boyes</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/q776847737762g52">view publication</a></span></p><p>Human immunodeficiency virus (HIV) infection is associated with the loss of the two principal types of dendritic cell (DC), myeloid DC (mDC) and plasmacytoid DC (pDC), but the mechanism of this loss and its relationship to AIDS pathogenesis remain ill-defined. The nonhuman primate is a powerful model to dissect this response for several reasons. Both DC subsets have been ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 228-234, 2011</cite>]]></description></item><item><title>Mechanisms by which HIV envelope minimizes immunogenicity</title><link>http://academic.research.microsoft.com/Publication/47624378</link><pubDate>Mon, 20 May 2013 07:44:51 GMT</pubDate><guid isPermaLink="false">47624378</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/53802675">Haixiang Jiang</a>, <a href="http://academic.research.microsoft.com/Author/11205723">Larry Liao</a>, <a href="http://academic.research.microsoft.com/Author/3220030">David C. Montefiori</a>, <a href="http://academic.research.microsoft.com/Author/23729333">Michael M. Frank</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/aq7734160r284400.pdf">view publication</a></span></p><p>With many viruses, vaccines containing the appropriate envelope antigens have provided strong and long lasting immunity. Not so with HIV-1 envelope, despite two decades of experience with various envelope and core constituent vaccines, protection provided has been weak or absent. Our laboratory has been systematically investigating the characteristics of HIV-1 envelope gp140, the principle HIV-1 envelope protein ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 147-158, 2011</cite>]]></description></item><item><title>Orchestrating T-cell receptor α gene assembly through changes in chromatin structure and organization</title><link>http://academic.research.microsoft.com/Publication/47752180</link><pubDate>Mon, 20 May 2013 07:44:50 GMT</pubDate><guid isPermaLink="false">47752180</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/53670096">Han-Yu Shih</a>, <a href="http://academic.research.microsoft.com/Author/24617681">Bingtao Hao</a>, <a href="http://academic.research.microsoft.com/Author/23401953">Michael S. Krangel</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/l81472278433p853.pdf">view publication</a></span></p><p>V(D)J recombination is regulated through changes in chromatin structure that allow recombinase proteins access to recombination signal sequences and through changes in three-dimensional chromatin organization that bring pairs of distant recombination signal sequences into proximity. The Tcra/Tcrd locus is complex and undergoes distinct recombination programs in double negative and double positive thymocytes that lead to the ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 192-201, 2011</cite>]]></description></item><item><title>Targeting myeloid regulatory cells in cancer by chemotherapeutic agents</title><link>http://academic.research.microsoft.com/Publication/48826312</link><pubDate>Mon, 20 May 2013 07:44:49 GMT</pubDate><guid isPermaLink="false">48826312</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/47297454">Hiam Naiditch</a>, <a href="http://academic.research.microsoft.com/Author/21199648">Michael R. Shurin</a>, <a href="http://academic.research.microsoft.com/Author/10997853">Galina V. Shurin</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/l156733449901645.pdf">view publication</a></span></p><p>Recent findings in humans and numerous experimental models provide evidence of the important role of immune regulatory cells in cancer and various diseases. “Myeloid regulatory cells” (MRC) include myeloid-derived suppressor cells, regulatory dendritic cells, regulatory macrophages, and subsets of granulocytes that expand during pathologic conditions and that have the ability to suppress cellular immunity. A decrease in MRC population ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 276-285, 2011</cite>]]></description></item><item><title>Impaired pulmonary immunity post-bone marrow transplant</title><link>http://academic.research.microsoft.com/Publication/48139391</link><pubDate>Mon, 20 May 2013 07:44:48 GMT</pubDate><guid isPermaLink="false">48139391</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/25440879">Stephanie M. Coomes</a>, <a href="http://academic.research.microsoft.com/Author/39888457">Leah L. N. Hubbard</a>, <a href="http://academic.research.microsoft.com/Author/53413814">Bethany B. Moore</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/k2815qv645424312">view publication</a></span></p><p>Infectious complications are a serious cause of morbidity and mortality following hematopoietic stem cell transplantation (HSCT), and the lung is a particular target organ post-transplant. Our laboratory has used a murine bone marrow transplant model to study alterations in immunity that occur as a result of transplantation. Our studies focus on immune responses that occur following immune cell reconstitution ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 1, pp. 78-86, 2011</cite>]]></description></item><item><title>Role of neurokinin-1 receptor in the initiation and maintenance of skin chronic inflammatory diseases</title><link>http://academic.research.microsoft.com/Publication/48848248</link><pubDate>Mon, 20 May 2013 07:44:47 GMT</pubDate><guid isPermaLink="false">48848248</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/37244854">Sherrie J. Divito</a>, <a href="http://academic.research.microsoft.com/Author/23812996">Adrian E. Morelli</a>, <a href="http://academic.research.microsoft.com/Author/23922875">Adriana T. Larregina</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/rn436536204n7r3x">view publication</a></span></p><p>To fulfill its immunologic functions, the skin is richly populated with dendritic cells (DCs), the most potent professional Ag-processing and Ag-presenting cells of the immune system. The immune-stimulatory and tolerogenic functions of skin DCs are regulated by the immune and neuroendocrine systems. Pro-inflammatory neuropeptides like substance P and calcitonin gene-related peptide secreted by cutaneous Aδ ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 195-201, 2011</cite>]]></description></item><item><title>Apoptosis and autophagy in the regulation of T lymphocyte function</title><link>http://academic.research.microsoft.com/Publication/47624561</link><pubDate>Mon, 20 May 2013 07:44:46 GMT</pubDate><guid isPermaLink="false">47624561</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/28055682">Alexis Dunkle</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/av8838px1838617v">view publication</a></span></p><p>During the development and normal function of T lymphocytes, the cells are subject to several checkpoints at which they must “decide” to live or die. At these critical times and during homeostasis, the molecules that regulate the classical apoptotic pathways and survival pathways such as autophagy have critical roles in controlling this decision. Our laboratory has focused on the roles ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 70-86, 2011</cite>]]></description></item><item><title>Regulation of NF-κB induction by TCR/CD28</title><link>http://academic.research.microsoft.com/Publication/48799200</link><pubDate>Mon, 20 May 2013 07:44:45 GMT</pubDate><guid isPermaLink="false">48799200</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/2996767">Jing Cheng</a>, <a href="http://academic.research.microsoft.com/Author/23719247">Angela Montecalvo</a>, <a href="http://academic.research.microsoft.com/Author/23454469">Lawrence P. Kane</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/66702164n648050g">view publication</a></span></p><p>NF-κB family transcription factors are a common downstream target for inducible transcription mediated by many different cell-surface receptors, especially those receptors involved in inflammation and adaptive immunity. It is now clear that different classes of receptors employ different proximal signaling strategies to activate the common NF-κB signaling components, such as the IKK complex. For antigen receptors expressed ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 113-117, 2011</cite>]]></description></item><item><title>CD8 + T-cell-mediated control of HIV1 and SIV infection</title><link>http://academic.research.microsoft.com/Publication/47922425</link><pubDate>Mon, 20 May 2013 07:44:44 GMT</pubDate><guid isPermaLink="false">47922425</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/7181034">Stephanie A. Freel</a>, <a href="http://academic.research.microsoft.com/Author/27138315">Kevin O. Saunders</a>, <a href="http://academic.research.microsoft.com/Author/18243721">Georgia D. Tomaras</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/uq541vw107r42j98.pdf">view publication</a></span></p><p>A detailed understanding of the cellular response to human immunodeficiency virus (HIV-1) infection is needed to inform prevention and therapeutic strategies that aim to contain the AIDS pandemic. The cellular immune response plays a critical role in reducing viral load in HIV-1 infection and in the nonhuman primate model of SIV infection. Much of this virus suppressive activity ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 135-146, 2011</cite>]]></description></item><item><title>Prevention of GVHD without losing GVL effect: windows of opportunity</title><link>http://academic.research.microsoft.com/Publication/48364066</link><pubDate>Mon, 20 May 2013 07:44:43 GMT</pubDate><guid isPermaLink="false">48364066</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/47487963">Ping Zhang</a>, <a href="http://academic.research.microsoft.com/Author/47643866">Benny J. Chen</a>, <a href="http://academic.research.microsoft.com/Author/18250843">Nelson J. Chao</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/x218206772h83434">view publication</a></span></p><p>Allogeneic hematopoietic cell transplantation has developed into a most successful form of immunotherapy for hematologic malignancies in the past 50 years. However, its effectiveness and wider applications have been greatly limited by the development of graft-versus-host disease (GVHD), a potentially lethal side effect associated with this procedure. Since the main effectors for both graft-versus-leukemia (GVL) effect and ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 49-55, 2011</cite>]]></description></item><item><title>On the logic of restrictive recognition of peptide by the T-cell antigen receptor</title><link>http://academic.research.microsoft.com/Publication/47603148</link><pubDate>Mon, 20 May 2013 07:44:42 GMT</pubDate><guid isPermaLink="false">47603148</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/18353094">Melvin Cohn</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/441tw2157347604r">view publication</a></span></p><p>This essay provides an analysis of the inadequacy of the current view of restrictive recognition of peptide by the T-cell antigen receptor. A competing model is developed, and the experimental evidence for the prevailing model is reinterpreted in the new framework. The goal is to contrast the two models with respect to their consistency, coverage of the data, explanatory ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 1, pp. 49-68, 2011</cite>]]></description></item><item><title>Pneumocystis infection and the pathogenesis of chronic obstructive pulmonary disease</title><link>http://academic.research.microsoft.com/Publication/48793682</link><pubDate>Mon, 20 May 2013 07:44:41 GMT</pubDate><guid isPermaLink="false">48793682</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/5029447">Karen A. Norris</a>, <a href="http://academic.research.microsoft.com/Author/11263016">Alison Morris</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/244728452570647k">view publication</a></span></p><p>With increases in the immunocompromised patient population and aging of the HIV+ population, the risk of serious fungal infections and their complications will continue to rise. In these populations, infection with the fungal opportunistic pathogen Pneumocystis jirovecii remains a leading cause of morbidity and mortality. Infection with Pneumocystis (Pc) has been shown to be associated with the development of chronic obstructive ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 175-180, 2011</cite>]]></description></item><item><title>Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes</title><link>http://academic.research.microsoft.com/Publication/47628721</link><pubDate>Mon, 20 May 2013 07:44:40 GMT</pubDate><guid isPermaLink="false">47628721</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/52287143">Rebecca H. Buckley</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/c3p87167u01075m8.pdf">view publication</a></span></p><p>Severe combined immunodeficiency (SCID) is a syndrome of diverse genetic cause characterized by profound deficiencies of T- and B-cell function and, in some types, also of NK cells and function. Mutations in thirteen different genes have been found to cause this condition, which is uniformly fatal in the first 2 years of life unless immune reconstitution can be accomplished. In ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 25-43, 2011</cite>]]></description></item><item><title>Immunology at Duke: 2011</title><link>http://academic.research.microsoft.com/Publication/47722556</link><pubDate>Mon, 20 May 2013 07:44:39 GMT</pubDate><guid isPermaLink="false">47722556</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23401953">Michael S. Krangel</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/k53p8143t21h0648">view publication</a></span></p><p /><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 1-2, 2011</cite>]]></description></item><item><title>Preface: Happy 10th anniversary!</title><link>http://academic.research.microsoft.com/Publication/48835888</link><pubDate>Mon, 20 May 2013 07:44:38 GMT</pubDate><guid isPermaLink="false">48835888</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23680587">Olivera J. Finn</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/n6h84j7l2q151720">view publication</a></span></p><p /><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 103-104, 2011</cite>]]></description></item><item><title>The role of iron in the immune response to bacterial infection</title><link>http://academic.research.microsoft.com/Publication/47958984</link><pubDate>Mon, 20 May 2013 07:44:37 GMT</pubDate><guid isPermaLink="false">47958984</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/4396212">Bobby J. Cherayil</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/w53t41m5783731m5.pdf">view publication</a></span></p><p>My laboratory has been interested for some time in the influence of iron, a nutrient that is essential for both microbial pathogens and their mammalian hosts, on the course of infectious disease. Our studies indicate that alterations in the expression of host molecules that sequester or transport iron can have direct effects on pathogen growth and can also have an ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 1, pp. 1-9, 2011</cite>]]></description></item><item><title>Role of TNF superfamily ligands in innate immunity</title><link>http://academic.research.microsoft.com/Publication/48834131</link><pubDate>Mon, 20 May 2013 07:44:36 GMT</pubDate><guid isPermaLink="false">48834131</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23683699">Nikola L. Vujanovic</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/n204744x2up12458">view publication</a></span></p><p>Natural killer (NK) cells and dendritic cells (DCs) are essential effector cells of the innate immune system that rapidly recognize and eliminate microbial pathogens and abnormal cells, and induce and regulate adaptive immune functions. While NK cells express perforin and granzymes in the lysosomal granules and transmembrane tumor necrosis factor superfamily ligands (tmTNFSFL) on the plasma membrane, DCs express only ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 159-174, 2011</cite>]]></description></item><item><title>Immunotherapeutic potential of oncolytic vaccinia virus</title><link>http://academic.research.microsoft.com/Publication/48850326</link><pubDate>Mon, 20 May 2013 07:44:35 GMT</pubDate><guid isPermaLink="false">48850326</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/4213586">Steve H. Thorne</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/t4vu662157440256">view publication</a></span></p><p>There has recently been resurgence in interest for the use of replication-selective (oncolytic) viruses for the treatment of cancers. This has been fueled by positive clinical data and the promise provided by next-generation vectors that are better targeted and display enhanced therapeutic potential. One factor that has led to more effective oncolytic vectors has been a greater appreciation ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 50, no. 2, pp. 286-293, 2011</cite>]]></description></item><item><title>T-lymphocyte recovery and function after cord blood transplantation</title><link>http://academic.research.microsoft.com/Publication/48150250</link><pubDate>Mon, 20 May 2013 07:44:34 GMT</pubDate><guid isPermaLink="false">48150250</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23612132">Paul Szabolcs</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/k8715v4389721562.pdf">view publication</a></span></p><p>The Szabolcs laboratory is focused on understanding the biology of donor-derived cellular immunity in recipients of allogeneic hematopoietic cell transplantation that can be translated into new immunotherapy strategies. To this end, we are focused on developing novel laboratory approaches to analyze and augment immune recovery for high risk patient cohorts without increasing graft-versus-host disease. Much of our ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 49, no. 1, pp. 56-69, 2011</cite>]]></description></item><item><title>High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation</title><link>http://academic.research.microsoft.com/Publication/34424619</link><pubDate>Mon, 20 May 2013 07:44:33 GMT</pubDate><guid isPermaLink="false">34424619</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/24822006">Leo Luznik</a>, <a href="http://academic.research.microsoft.com/Author/53558368">Ephraim J. Fuchs</a><span style="margin-left:20px">(Citations:6)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/948897h181g85788">view publication</a></span></p><p>Graft-versus-host disease, or GVHD, is a major complication of allogeneic hematopoietic stem cell transplantation (alloHSCT) for the treatment of hematologic malignancies. Here, we describe a novel method for preventing GVHD after alloHSCT using high-dose, post-transplantation cyclophosphamide (Cy). Post-transplantation Cy promotes tolerance in alloreactive host and donor T cells, leading to suppression of both graft rejection ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 65-77, 2010</cite>]]></description></item><item><title>Enhancement of anti-tumor immunity by photodynamic therapy</title><link>http://academic.research.microsoft.com/Publication/34424598</link><pubDate>Mon, 20 May 2013 07:44:32 GMT</pubDate><guid isPermaLink="false">34424598</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23677526">Sandra O. Gollnick</a>, <a href="http://academic.research.microsoft.com/Author/27497774">Craig M. Brackett</a><span style="margin-left:20px">(Citations:8)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/2451l15547871501.pdf">view publication</a></span></p><p>Photodynamic therapy (PDT) is an FDA-approved modality that rapidly eliminates local tumors, resulting in cure of early disease and palliation of advanced disease. PDT was originally considered to be a local treatment; however, both pre-clinical and clinical studies have shown that local PDT treatment of tumors can enhance systemic anti-tumor immunity. The current state of investigations into ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 216-226, 2010</cite>]]></description></item><item><title>Incompatible kidney transplantation: lessons from a decade of desensitization and paired kidney exchange</title><link>http://academic.research.microsoft.com/Publication/34424635</link><pubDate>Mon, 20 May 2013 07:44:31 GMT</pubDate><guid isPermaLink="false">34424635</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/50139621">Daniel S. Warren</a>, <a href="http://academic.research.microsoft.com/Author/7709047">Robert A. Montgomery</a><span style="margin-left:20px">(Citations:6)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/qv616l1wt2u05537">view publication</a></span></p><p>Human leukocyte antigen (HLA) sensitization and ABO incompatibility continue to pose significant barriers to further expansion of live donor renal transplantation. However, the recent development of effective desensitization protocols and creative paired donation strategies demonstrates that the presence of circulating donor HLA-specific antibodies and the use of ABO incompatible organs should no longer be considered contraindications for renal transplantation. ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 257-264, 2010</cite>]]></description></item><item><title>Regulatory T cells and immune tolerance to tumors</title><link>http://academic.research.microsoft.com/Publication/34424594</link><pubDate>Mon, 20 May 2013 07:44:30 GMT</pubDate><guid isPermaLink="false">34424594</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/4745697">Xuefang Cao</a><span style="margin-left:20px">(Citations:5)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/1g6v0n8141708v41.pdf">view publication</a></span></p><p>Immune cells infiltrate tumors and make up a significant component of the multicellular cancer micro-environment, yet the immune system often fails to prevent tumor formation and progression. One explanation for this paradox is the presence of tolerance-promoting regulatory T cells (Tregs) that counteract antitumor immune cells. Tregs were known to be essential for maintaining self-tolerance. Recently, Tregs ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 79-93, 2010</cite>]]></description></item><item><title>IgE antibody-specific activity in human allergic disease</title><link>http://academic.research.microsoft.com/Publication/34424612</link><pubDate>Mon, 20 May 2013 07:44:29 GMT</pubDate><guid isPermaLink="false">34424612</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/37066469">Robert G. HamiltonDonald</a>, <a href="http://academic.research.microsoft.com/Author/3700710">Donald W. MacGlashan</a>, <a href="http://academic.research.microsoft.com/Author/53581996">Sarbjit S. Saini</a><span style="margin-left:20px">(Citations:4)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/142w2818816h3867.pdf">view publication</a></span></p><p>IgE antibody concentration, affinity, clonality and specific activity (also known as the allergen-specific IgE to total IgE ratio) influence the translation of IgE responses into clinically evident allergic symptoms following allergen exposure. Reported IgE-specific activity levels &amp;gt;3–4% place allergic individuals undergoing anti-IgE (Omalizumab®) therapy at a disadvantage for poor resolution of their allergy symptoms following ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 273-284, 2010</cite>]]></description></item><item><title>Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms</title><link>http://academic.research.microsoft.com/Publication/34424603</link><pubDate>Mon, 20 May 2013 07:44:28 GMT</pubDate><guid isPermaLink="false">34424603</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/27497778">Wasif Riaz</a>, <a href="http://academic.research.microsoft.com/Author/21580528">Francisco J. Hernandez-Ilizaliturri</a>, <a href="http://academic.research.microsoft.com/Author/23823378">Myron S. Czuczman</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/66441308112w3n88">view publication</a></span></p><p>Rituximab is a chimeric monoclonal anti-CD20 antibody and was the first monoclonal antibody (mAb) therapy approved by FDA (Food and Drug Administration) for the treatment of B-cell lymphoma. It has revolutionized the treatment of patients with CD20-positive non-Hodgkin’s lymphoma and CLL. Rituximab is currently being used in virtually all patients with B-cell lymphomas either alone ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 192-205, 2010</cite>]]></description></item><item><title>Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia</title><link>http://academic.research.microsoft.com/Publication/34424602</link><pubDate>Mon, 20 May 2013 07:44:27 GMT</pubDate><guid isPermaLink="false">34424602</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/27497777">Adrienne J. Peer</a>, <a href="http://academic.research.microsoft.com/Author/26097627">Melissa J. Grimm</a>, <a href="http://academic.research.microsoft.com/Author/26600964">Evan R. Zynda</a>, <a href="http://academic.research.microsoft.com/Author/23626730">Elizabeth A. Repasky</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/m706761pr61v6uu9">view publication</a></span></p><p>There is increasing documentation of significant survival benefits achieved in cancer patients treated with hyperthermia in combination with radiation and/or chemotherapy. Most evidence collected regarding the mechanisms by which hyperthermia positively influences tumor control has centered on in vitro data showing the ability of heat shock temperatures (usually above 42°C) to result in radio- or chemosensitization. However, these high ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 137-154, 2010</cite>]]></description></item><item><title>High-dose cyclophosphamide for autoimmunity and alloimmunity</title><link>http://academic.research.microsoft.com/Publication/34424630</link><pubDate>Mon, 20 May 2013 07:44:26 GMT</pubDate><guid isPermaLink="false">34424630</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/18401017">Robert A. Brodsky</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/b7m53830658u5811.pdf">view publication</a></span></p><p>High-dose cyclophosphamide (high-CY) is a potent immunosuppressive regimen that is increasingly used to mitigate both autoimmune and alloimmune conditions. Differential expression of aldehyde dehydrogenase between hematopoietic stem cells and lymphocytes accounts for the differential sensitivity of these cells to high-CY and explains why this regimen is immunosuppressive but not myeloablative. This article describes the clinical translation of ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 179-184, 2010</cite>]]></description></item><item><title>Cell type-specific regulation of IL10 expression in inflammation and disease</title><link>http://academic.research.microsoft.com/Publication/34424627</link><pubDate>Mon, 20 May 2013 07:44:25 GMT</pubDate><guid isPermaLink="false">34424627</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/24658723">Christian M. Hedrich</a>, <a href="http://academic.research.microsoft.com/Author/23707601">Jay H. Bream</a><span style="margin-left:20px">(Citations:5)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/j651w4p24m221412.pdf">view publication</a></span></p><p>IL-10 plays an essential part in controlling inflammation and instructing adaptive immune responses. Consequently, dysregulation of IL-10 is linked with susceptibility to numerous infectious and autoimmune diseases in mouse models and in humans. It has become increasingly clear that appropriate temporal/spatial expression of IL-10 may be the key to how IL-10 contributes to the delicate ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 185-206, 2010</cite>]]></description></item><item><title>Recovery from viral encephalomyelitis: immune-mediated noncytolytic virus clearance from neurons</title><link>http://academic.research.microsoft.com/Publication/34424626</link><pubDate>Mon, 20 May 2013 07:44:24 GMT</pubDate><guid isPermaLink="false">34424626</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/4596908">Diane E. Griffin</a><span style="margin-left:20px">(Citations:3)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/21l680536854j55w">view publication</a></span></p><p>Viral encephalomyelitis is caused by virus infections of neurons in the brain and spinal cord. Recovery is dependent on immune-mediated control and clearance of virus from these terminally differentiated essential cells. Preservation of neuronal function is essential for prevention of neurologic sequelae such as paralysis, seizures and cognitive deficits. Using the model system of Sindbis virus-induced encephalomyelitis in ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 123-133, 2010</cite>]]></description></item><item><title>Regulating functional cell fates in CD8 T cells</title><link>http://academic.research.microsoft.com/Publication/34424611</link><pubDate>Mon, 20 May 2013 07:44:23 GMT</pubDate><guid isPermaLink="false">34424611</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23643271">Protul A. Shrikant</a>, <a href="http://academic.research.microsoft.com/Author/11345822">Rajesh Rao</a>, <a href="http://academic.research.microsoft.com/Author/23542688">Qingsheng Li</a>, <a href="http://academic.research.microsoft.com/Author/26012753">Joshua Kesterson</a>, <a href="http://academic.research.microsoft.com/Author/12384926">Cheryl Eppolito</a>, <a href="http://academic.research.microsoft.com/Author/5155172">Axel Mischo</a>, <a href="http://academic.research.microsoft.com/Author/22832831">Pankaj Singhal</a><span style="margin-left:20px">(Citations:3)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/686t6l41x35710g2.pdf">view publication</a></span></p><p>The attributes of specificity and memory enable CD8+ T cells to provide long-lasting protection against a variety of challenges. Although, the importance of CD8+ T cells for protection against intracellular infections and transformation is well-established, the functional type; effector phenotypes (Tc1, Tc2, Tc17 and/or Tcreg) and/or memory (effector or central), of CD8+ T cells most desirable ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 12-22, 2010</cite>]]></description></item><item><title>Signaling through the P38 and ERK pathways: a common link between HIV replication and the immune response</title><link>http://academic.research.microsoft.com/Publication/34424641</link><pubDate>Mon, 20 May 2013 07:44:22 GMT</pubDate><guid isPermaLink="false">34424641</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/27497794">Robert L. Furler</a>, <a href="http://academic.research.microsoft.com/Author/4969482">Christel H. Uittenbogaart</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/n501022833152560">view publication</a></span></p><p>One of the defining characteristics of HIV is its ability to manipulate the human immune response to promote its own replication. Since the beginning of the epidemic, there has been controversy whether a robust immune response to the virus is beneficial or detrimental for the host. Therefore, the effects of HIV on signaling pathways and cytokine production need to be ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 48, no. 1, pp. 99-109, 2010</cite>]]></description></item><item><title>Analysis of gene profile, steady state proliferation and apoptosis of double-negative T cells in the periphery and gut epithelium provides new insights into the biological functions of the Fas pathway</title><link>http://academic.research.microsoft.com/Publication/34424616</link><pubDate>Mon, 20 May 2013 07:44:21 GMT</pubDate><guid isPermaLink="false">34424616</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/18262306">Abdel Rahim A. Hamad</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/g5r01131m5716j3j">view publication</a></span></p><p>Considerable progress has been made in understanding the Fas pathway at the molecular and cellular levels, but fundamental questions about the overall biological role of the Fas pathway remain unresolved. A major question is why lymphoproliferation caused by the lpr mutation of Fas and gld mutation of FasL ligand (FasL) is dominated by CD4− and CD8− double-negative αβ T ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 134-142, 2010</cite>]]></description></item><item><title>Immunogenetics and immunology in transplantation</title><link>http://academic.research.microsoft.com/Publication/34424638</link><pubDate>Mon, 20 May 2013 07:44:20 GMT</pubDate><guid isPermaLink="false">34424638</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/9232671">Andrea A. Zachary</a>, <a href="http://academic.research.microsoft.com/Author/21272001">Dessislava Kopchaliiska</a>, <a href="http://academic.research.microsoft.com/Author/53547004">Annette M. Jackson</a>, <a href="http://academic.research.microsoft.com/Author/23308755">Mary S. Leffell</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/d11u771r80ulw38x.pdf">view publication</a></span></p><p>Advances in immunogenetics and histocompatibility have facilitated the clinical transplantation of solid organs and tissues. Improved definition of HLA antigens, alleles, and haplotypes has clarified the diversity of the HLA system among different racial/ethnic populations. Knowledge of allele and haplotypes frequencies derived from these studies can be applied to the estimates of transplant compatibility and the likelihood finding suitable ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 232-239, 2010</cite>]]></description></item><item><title>Genetic and biochemical regulation of CD4 T cell effector differentiation: insights from examination of T cell clonal anergy</title><link>http://academic.research.microsoft.com/Publication/34424624</link><pubDate>Mon, 20 May 2013 07:44:19 GMT</pubDate><guid isPermaLink="false">34424624</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/27743708">Christopher J. Gamper</a>, <a href="http://academic.research.microsoft.com/Author/10544899">Jonathan D. Powell</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/9777357106213088">view publication</a></span></p><p>The two-signal model of T cell activation states that antigen recognition by TCR provides a tolerogenic signal (termed Signal 1) unless the T cell receives simultaneous costimulation (Signal 2) that permits antigen recognition to prime activation. Our efforts to characterize genetic and biochemical factors resulting from Signal 1 alone have identified signaling molecules, transcription factors, and an epigenetic regulator ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 162-171, 2010</cite>]]></description></item><item><title>Translating insights from persistent LCMV infection into anti-HIV immunity</title><link>http://academic.research.microsoft.com/Publication/34424642</link><pubDate>Mon, 20 May 2013 07:44:18 GMT</pubDate><guid isPermaLink="false">34424642</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/27497491">Elizabeth B. Wilson</a>, <a href="http://academic.research.microsoft.com/Author/5110088">David G. Brooks</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/d4k450n06p207038.pdf">view publication</a></span></p><p>Human immunodeficiency virus (HIV) is a major global health concern with more than 30 million individuals currently infected worldwide. To date, attempts to stimulate protective immunity to viral components of HIV have been unsuccessful in preventing or clearing infection. Lymphocytic choriomeningitis virus (LCMV) is an established murine model of persistent viral infection that has been instrumental in illuminating several critical ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 48, no. 1, pp. 3-13, 2010</cite>]]></description></item><item><title>Immune regulation in the retina</title><link>http://academic.research.microsoft.com/Publication/34424625</link><pubDate>Mon, 20 May 2013 07:44:17 GMT</pubDate><guid isPermaLink="false">34424625</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23639601">Barbara Detrick</a>, <a href="http://academic.research.microsoft.com/Author/23713141">John J. Hooks</a><span style="margin-left:20px">(Citations:3)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/j572p96545271477">view publication</a></span></p><p>Immune reactivity in the retina can be critically important in inflammation and infections, but regulation of this response is essential. The retinal pigment epithelial (RPE), a unique retinal cell, displays a number of essential functions to support the health of the retina. In this review, we highlight how the RPE cell plays a pivotal role in immune defense. The RPE ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 153-161, 2010</cite>]]></description></item><item><title>Oral transgenic plant-based vaccine for hepatitis B</title><link>http://academic.research.microsoft.com/Publication/34424606</link><pubDate>Mon, 20 May 2013 07:44:16 GMT</pubDate><guid isPermaLink="false">34424606</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/24222783">Yasmin Thanavala</a>, <a href="http://academic.research.microsoft.com/Author/24955140">Amit A. Lugade</a><span style="margin-left:20px">(Citations:3)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/4201qpw0231t6791.pdf">view publication</a></span></p><p>In addition to improving vaccine formulations in order to elicit robust and long-lasting immune responses, there is also an increasing need for improving the manner in which these vaccines are delivered. As most current vaccines are administered by injection by a health care giver, there is the ever-present danger of needlestick injuries. Therefore, needle-free vaccinations are a ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 4-11, 2010</cite>]]></description></item><item><title>HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma</title><link>http://academic.research.microsoft.com/Publication/34424647</link><pubDate>Mon, 20 May 2013 07:44:15 GMT</pubDate><guid isPermaLink="false">34424647</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/21486326">Marta Epeldegui</a>, <a href="http://academic.research.microsoft.com/Author/27048389">Elena Vendrame</a>, <a href="http://academic.research.microsoft.com/Author/5675623">Otoniel Martínez-Maza</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/588776037g1x5173">view publication</a></span></p><p>HIV infection is associated with a much higher risk for the development of non-Hodgkin lymphoma (AIDS-NHL). The principal causes of lymphomagenesis in HIV-infected individuals are thought to be the loss of immune function seen in HIV infection, which results in the loss of immunoregulation of Epstein–Barr virus-infected B cells, as well as HIV infection-associated ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 48, no. 1, pp. 72-83, 2010</cite>]]></description></item><item><title>Autoimmune thyroiditis research at Johns Hopkins University</title><link>http://academic.research.microsoft.com/Publication/34424632</link><pubDate>Mon, 20 May 2013 07:44:14 GMT</pubDate><guid isPermaLink="false">34424632</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23945769">C. Lynne Burek</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/r6568x050u673776">view publication</a></span></p><p>Autoimmune thyroiditis is an organ-specific autoimmune disorder characterized by infiltration of the thyroid gland by lymphocytic inflammatory cells, often followed by hypothyroidism due to destruction and replacement of the follicular tissue. Dr. Noel Rose and members of his laboratory at Johns Hopkins University have continued to study autoimmunity using autoimmune thyroiditis as a model. Autoimmune thyroiditis is multifactorial, with ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 207-215, 2010</cite>]]></description></item><item><title>Non-canonical Wnt signaling pathways in hematopoiesis</title><link>http://academic.research.microsoft.com/Publication/34424599</link><pubDate>Mon, 20 May 2013 07:44:13 GMT</pubDate><guid isPermaLink="false">34424599</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/27497775">Kathleen Kokolus</a>, <a href="http://academic.research.microsoft.com/Author/37052707">Michael J. Nemeth</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/r707ux5u22l62870.pdf">view publication</a></span></p><p>Hematopoietic stem cells (HSCs) are a rare population of cells that are responsible for life-long generation of blood cells of all lineages. In order to maintain their numbers, HSCs must establish a balance between the opposing cell fates of self-renewal and initiation of hematopoietic differentiation. Multiple signaling pathways have been implicated in the regulation of HSC cell fate. ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 155-164, 2010</cite>]]></description></item><item><title>Mechanisms involved in antibody- and complement-mediated allograft rejection</title><link>http://academic.research.microsoft.com/Publication/34424639</link><pubDate>Mon, 20 May 2013 07:44:12 GMT</pubDate><guid isPermaLink="false">34424639</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/12375402">Barbara A. Wasowska</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/g4832785758j5287.pdf">view publication</a></span></p><p>Antibody-mediated rejection has become critical clinically because this form of rejection is usually unresponsive to conventional anti-rejection therapy, and therefore, it has been recognized as a major cause of allograft loss. Our group developed experimental animal models of vascularized organ transplantation to study pathogenesis of antibody- and complement-mediated endothelial cell injury leading to graft rejection. In this ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 25-44, 2010</cite>]]></description></item><item><title>Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence</title><link>http://academic.research.microsoft.com/Publication/34424617</link><pubDate>Mon, 20 May 2013 07:44:11 GMT</pubDate><guid isPermaLink="false">34424617</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/27497783">Kelly P. Burke</a>, <a href="http://academic.research.microsoft.com/Author/53702716">Andrea L. Cox</a><span style="margin-left:20px">(Citations:3)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/x77k522334q18611">view publication</a></span></p><p>Hepatitis C virus (HCV) infects over 170 million people worldwide and is a leading cause of cirrhosis and hepatocellular carcinoma. Approximately 80% of those acutely infected clear the infection, whereas the remaining 20% progress to chronic infection. Hepatitis C thus provides a model in which successful and unsuccessful responses can be compared to better understand the human response to viral ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 216-227, 2010</cite>]]></description></item><item><title>Prospects of a novel vaccination strategy for human gamma-herpesviruses</title><link>http://academic.research.microsoft.com/Publication/34424646</link><pubDate>Mon, 20 May 2013 07:44:10 GMT</pubDate><guid isPermaLink="false">34424646</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/38211950">Ting-Ting WuMarcia</a>, <a href="http://academic.research.microsoft.com/Author/23581959">Marcia A. Blackman</a>, <a href="http://academic.research.microsoft.com/Author/43680902">Ren Sun</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/v0374018p4769631">view publication</a></span></p><p>Due to the oncogenic potential associated with persistent infection of human gamma-herpesviruses, including Epstein–Barr virus (EBV or HHV-4) and Kaposi’s sarcoma-associated herpesvirus (KSHV or HHV-8), vaccine development has focused on subunit vaccines. However, the results using an animal model of mouse infection with a related rodent virus, murine gamma-herpesvirus 68 (MHV-68, γHV-68, ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 48, no. 1, pp. 122-146, 2010</cite>]]></description></item><item><title>Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression</title><link>http://academic.research.microsoft.com/Publication/34424595</link><pubDate>Mon, 20 May 2013 07:44:09 GMT</pubDate><guid isPermaLink="false">34424595</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/27497500">Matthew R. Farren</a>, <a href="http://academic.research.microsoft.com/Author/56692588">Louise M. Carlson</a>, <a href="http://academic.research.microsoft.com/Author/37103568">Kelvin P. Lee</a><span style="margin-left:20px">(Citations:3)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/vu4n1178131158hh">view publication</a></span></p><p>Tumor-mediated immune suppression occurs through multiple mechanisms, including dysregulation of dendritic cell differentiation. This block in differentiation results in fewer dendritic cells and an accumulation of immunosuppressive myeloid- derived suppressor cells and is thought to contribute to tumor outgrowth and to act as an impediment to successful anti-cancer immunotherapy. Tumor-mediated myeloid dysregulation is known to be Stat3 ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 165-176, 2010</cite>]]></description></item><item><title>Fine-tuning immune surveillance by fever-range thermal stress</title><link>http://academic.research.microsoft.com/Publication/34424596</link><pubDate>Mon, 20 May 2013 07:44:08 GMT</pubDate><guid isPermaLink="false">34424596</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/4165557">Daniel T. Fisher</a>, <a href="http://academic.research.microsoft.com/Author/27497501">Trupti D. Vardam</a>, <a href="http://academic.research.microsoft.com/Author/27497502">Jason B. Muhitch</a>, <a href="http://academic.research.microsoft.com/Author/23516454">Sharon S. Evans</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/w4v3w42t42404863">view publication</a></span></p><p>An effectively orchestrated immune response to infection and disease depends on efficient trafficking of lymphocytes across vascular beds at distinct tissue sites. Local inflammation and systemic fever increase immune surveillance to immune-relevant sites throughout the body. During the initiation phase of inflammation, this tightly regulated process improves leukocyte trafficking to the secondary lymphoid organs where they undergo activation and ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 177-188, 2010</cite>]]></description></item><item><title>What is the role of alternate splicing in antigen presentation by major histocompatibility complex class I molecules?</title><link>http://academic.research.microsoft.com/Publication/34424610</link><pubDate>Mon, 20 May 2013 07:44:07 GMT</pubDate><guid isPermaLink="false">34424610</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/26659759">Alan Belicha-VillanuevaJennifer</a>, <a href="http://academic.research.microsoft.com/Author/38211910">Jennifer Blickwedehl</a>, <a href="http://academic.research.microsoft.com/Author/27497785">Sarah McEvoy</a>, <a href="http://academic.research.microsoft.com/Author/27497786">Michelle Golding</a>, <a href="http://academic.research.microsoft.com/Author/23677526">Sandra O. Gollnick</a>, <a href="http://academic.research.microsoft.com/Author/12379058">Naveen Bangia</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/17622328148416m0">view publication</a></span></p><p>The expression of major histocompatibility complex (MHC) class I molecules on the cell surface is critical for recognition by cytotoxic T lymphocytes (CTL). This recognition event leads to destruction of cells displaying MHC class I—viral peptide complexes or cells displaying MHC class I—mutant peptide complexes. Before they can be transported to the cell surface, MHC class I molecules ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 32-44, 2010</cite>]]></description></item><item><title>Generation of tolerogenic dendritic cells via the E-cadherin/β-catenin-signaling pathway</title><link>http://academic.research.microsoft.com/Publication/34424597</link><pubDate>Mon, 20 May 2013 07:44:06 GMT</pubDate><guid isPermaLink="false">34424597</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/4100818">Chunmei Fu</a>, <a href="http://academic.research.microsoft.com/Author/34755314">Aimin Jiang</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/t478j1600l654219">view publication</a></span></p><p>Besides their well-characterized role as the initiator of adaptive immune responses, dendritic cells (DCs) play a critical role in the induction and maintenance of self-tolerance, the failure of which could lead to autoimmune/inflammatory diseases. Although it is clear that tolerance is a property of DCs at the steady state, the molecular mechanisms governing their generation, function and ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 72-78, 2010</cite>]]></description></item><item><title>Reconstitution of self-tolerance after hematopoietic stem cell transplantation</title><link>http://academic.research.microsoft.com/Publication/34424618</link><pubDate>Mon, 20 May 2013 07:44:05 GMT</pubDate><guid isPermaLink="false">34424618</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23212778">Allan D. Hess</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/r77n4w382t34q2lj.pdf">view publication</a></span></p><p>Graft-versus-host disease (GVHD) is a major complication of allogeneic bone marrow or hematopoietic stem cell transplantation. GVHD is thought to be primarily due to the response of mature T cells transferred along with the bone marrow graft to foreign histocompatibility antigens expressed on host tissues. Recent studies, however, have challenged this paradigm set forth in the 1960s and ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 143-152, 2010</cite>]]></description></item><item><title>Quiescent T cells and HIV: an unresolved relationship</title><link>http://academic.research.microsoft.com/Publication/34424644</link><pubDate>Mon, 20 May 2013 07:44:04 GMT</pubDate><guid isPermaLink="false">34424644</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/5153813">Dimitrios N. Vatakis</a>, <a href="http://academic.research.microsoft.com/Author/27497798">Christopher C. Nixon</a>, <a href="http://academic.research.microsoft.com/Author/3011060">Jerome A. Zack</a><span style="margin-left:20px">(Citations:2)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/w1642770kk12n625.pdf">view publication</a></span></p><p>The ability of HIV to infect quiescent CD4+ T cells has been a topic of intense debate. While early studies suggested that the virus could not infect this particular T cell subset, subsequent studies using more sensitive protocols demonstrated that these cells could inefficiently support HIV infection. Additional studies showed that the kinetics of infection in quiescent cells was delayed ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 48, no. 1, pp. 110-121, 2010</cite>]]></description></item><item><title>Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection</title><link>http://academic.research.microsoft.com/Publication/34424613</link><pubDate>Mon, 20 May 2013 07:44:03 GMT</pubDate><guid isPermaLink="false">34424613</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/53564592">Scheherazade Sadegh-NasseriSateesh</a>, <a href="http://academic.research.microsoft.com/Author/55039221">Sateesh Natarajan</a>, <a href="http://academic.research.microsoft.com/Author/42133794">Chih-Ling Chou</a>, <a href="http://academic.research.microsoft.com/Author/23922743">Isamu Z. Hartman</a>, <a href="http://academic.research.microsoft.com/Author/10986491">Kedar Narayan</a>, <a href="http://academic.research.microsoft.com/Author/22989886">AeRyon Kim</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/27np05n504726407.pdf">view publication</a></span></p><p>T cells bearing αβ receptors recognize antigenic peptides bound to class I and class II glycoproteins encoded in the major histocompatibility complex (MHC). Cytotoxic and helper T cells respond respectively to peptide antigens derived from endogenous sources presented by MHC class I, and exogenous sources presented by MHC II, on antigen presenting cells. Differences in the MHC class I and ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 56-64, 2010</cite>]]></description></item><item><title>Review: Is lung inflammation associated with microbes and microbial toxins in cigarette tobacco smoke?</title><link>http://academic.research.microsoft.com/Publication/34424601</link><pubDate>Mon, 20 May 2013 07:44:02 GMT</pubDate><guid isPermaLink="false">34424601</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/25133883">John L. Pauly</a>, <a href="http://academic.research.microsoft.com/Author/39334943">Lauren A. Smith</a>, <a href="http://academic.research.microsoft.com/Author/27497776">Michael H. Rickert</a>, <a href="http://academic.research.microsoft.com/Author/10797057">Alan Hutson</a>, <a href="http://academic.research.microsoft.com/Author/38210554">Geraldine M. Paszkiewicz</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/e6268798747621j2.pdf">view publication</a></span></p><p>Chronic inflammation that has been observed for malignant and non-neoplastic lung diseases of smokers has been attributed to the numerous and diverse particulate (‘tar’)-phase and gas-phase chemicals in mainstream smoke, most of which arise from the burning of tobacco. The primary cell-mediator of lung inflammation is the macrophage. Most probably, inflammation is promoted also from some ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 127-136, 2010</cite>]]></description></item><item><title>PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer</title><link>http://academic.research.microsoft.com/Publication/34424605</link><pubDate>Mon, 20 May 2013 07:44:01 GMT</pubDate><guid isPermaLink="false">34424605</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/53031380">Ashwani K. Sood</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/h23625l5n3518q2g.pdf">view publication</a></span></p><p>Novel breast tumor antigens are needed to develop T cell and antibody-based vaccine immunotherapy approach against breast cancer. To this purpose, we have previously shown that PDEF is frequently over expressed in human breast tumors and exhibits highly restricted expression in normal human tissues that is primarily limited to normal prostate. Moreover, PDEF expression correlates with poor overall survival ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 206-215, 2010</cite>]]></description></item><item><title>Erratum to: Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence</title><link>http://academic.research.microsoft.com/Publication/34424608</link><pubDate>Mon, 20 May 2013 07:44:00 GMT</pubDate><guid isPermaLink="false">34424608</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/27497783">Kelly P. Burke</a>, <a href="http://academic.research.microsoft.com/Author/53702716">Andrea L. Cox</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/index/k27grp70107p2810.pdf">view publication</a></span></p><p /><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 285-285, 2010</cite>]]></description></item><item><title>Class I MHC molecules as probes of membrane patchiness: from biophysical measurements to modulation of immune responses</title><link>http://academic.research.microsoft.com/Publication/34424620</link><pubDate>Mon, 20 May 2013 07:43:59 GMT</pubDate><guid isPermaLink="false">34424620</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/36968930">Michael Edidin</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/h81t57pqp60r1114">view publication</a></span></p><p>Here I summarize decades of work using the biophysics of class I MHC molecules to probe the patchiness and heterogeneity of cell surfaces. This program began as a study of membranes generally. MHC molecules were a convenient probe. However, in recent years, it has become clear that the lateral distribution, clustering, of class I MHC molecules in the membrane affects ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 265-272, 2010</cite>]]></description></item><item><title>Controlling somatic hypermutation in immunoglobulin variable and switch regions</title><link>http://academic.research.microsoft.com/Publication/34424623</link><pubDate>Mon, 20 May 2013 07:43:58 GMT</pubDate><guid isPermaLink="false">34424623</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/6423309">Robert W. Maul</a>, <a href="http://academic.research.microsoft.com/Author/36903943">Patricia J. Gearhart</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/kl846472wh7u7505">view publication</a></span></p><p>Activation-induced deaminase (AID) is a B-cell-specific enzyme required for initiating the mechanisms of affinity maturation and isotype switching of antibodies. AID functions by deaminating cytosine to uracil in DNA, which initiates a cascade of events resulting in mutations and strand breaks in the immunoglobulin loci. There is an intricate interplay between faithful DNA repair and mutagenic DNA ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 113-122, 2010</cite>]]></description></item><item><title>Therapeutic HPV DNA vaccines</title><link>http://academic.research.microsoft.com/Publication/34424615</link><pubDate>Mon, 20 May 2013 07:43:57 GMT</pubDate><guid isPermaLink="false">34424615</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/53719066">Ken Lin</a>, <a href="http://academic.research.microsoft.com/Author/27497790">Elena Roosinovich</a>, <a href="http://academic.research.microsoft.com/Author/18609798">Barbara Ma</a>, <a href="http://academic.research.microsoft.com/Author/19220477">Chien-Fu Hung</a>, <a href="http://academic.research.microsoft.com/Author/3635970">T.-C. Wu</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/f2180m406h3vj545">view publication</a></span></p><p>It is now well established that most cervical cancers are causally associated with HPV infection. This realization has led to efforts to control HPV-associated malignancy through prevention or treatment of HPV infection. Currently, commercially available HPV vaccines are not designed to control established HPV infection and associated premalignant and malignant lesions. To treat and eradicate pre-existing HPV infections ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 86-112, 2010</cite>]]></description></item><item><title>TCF1 and β-catenin regulate T cell development and function</title><link>http://academic.research.microsoft.com/Publication/34424631</link><pubDate>Mon, 20 May 2013 07:43:56 GMT</pubDate><guid isPermaLink="false">34424631</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/15898">Qing Yu</a>, <a href="http://academic.research.microsoft.com/Author/53631856">Archna Sharma</a>, <a href="http://academic.research.microsoft.com/Author/23885342">Jyoti Misra Sen</a><span style="margin-left:20px">(Citations:1)</span><span style="margin-left:20px"><a href="http://www.springerlink.com/content/3r4g3pk86040411h">view publication</a></span></p><p>T cell factor-1 (TCF1) critically regulates T cell development. However, signals that control TCF1 function in developing and mature T cells remain unknown. TCF1 along with β-catenin activates gene transcription and in cooperation with Groucho family of proteins mediates gene repression. It has been established that the β-catenin-dependent gene expression is often downstream of the canonical ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 45-55, 2010</cite>]]></description></item><item><title>MHC class II regulation by epigenetic agents and microRNAs</title><link>http://academic.research.microsoft.com/Publication/34424607</link><pubDate>Mon, 20 May 2013 07:43:55 GMT</pubDate><guid isPermaLink="false">34424607</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23177729">Thomas B. Tomasi</a>, <a href="http://academic.research.microsoft.com/Author/5422601">William J. Magner</a>, <a href="http://academic.research.microsoft.com/Author/27497779">Jennifer L. Wiesen</a>, <a href="http://academic.research.microsoft.com/Author/27497780">Julian Z. Oshlag</a>, <a href="http://academic.research.microsoft.com/Author/27497781">Felicia Cao</a>, <a href="http://academic.research.microsoft.com/Author/27497782">Alex N. Pontikos</a>, <a href="http://academic.research.microsoft.com/Author/26098513">Christopher J. Gregorie</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/b27550v2483g6764.pdf">view publication</a></span></p><p>MicroRNAs have been shown to regulate gene expression both transcriptionally and translationally. Here, we examine evidence that various stresses regulate miRNAs which, in turn, regulate immune gene levels. Multiple studies are reviewed showing altered microRNA levels in normal cells under stress and in various disease states, including cancer. Unexpected was the finding that Dicer expression is altered by treatments with ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 45-58, 2010</cite>]]></description></item><item><title>Receptor-targeted anticancer therapy</title><link>http://academic.research.microsoft.com/Publication/34424604</link><pubDate>Mon, 20 May 2013 07:43:54 GMT</pubDate><guid isPermaLink="false">34424604</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23947390">Ben K. Seon</a>, <a href="http://academic.research.microsoft.com/Author/54711813">Yuro Haruta</a>, <a href="http://academic.research.microsoft.com/Author/7070162">Fumihiko Matsuno</a>, <a href="http://academic.research.microsoft.com/Author/6360827">Akinao Haba</a>, <a href="http://academic.research.microsoft.com/Author/6535954">Norihiko Takahashi</a>, <a href="http://academic.research.microsoft.com/Author/24042543">Xinwei She</a>, <a href="http://academic.research.microsoft.com/Author/56302667">Naoko Harada</a>, <a href="http://academic.research.microsoft.com/Author/24897838">Shima Uneda</a>, <a href="http://academic.research.microsoft.com/Author/21559317">Masanori Tsujie</a>, <a href="http://academic.research.microsoft.com/Author/27045868">Tomoko Tsujie</a>, <a href="http://academic.research.microsoft.com/Author/11083711">Hirofumi Toi</a>, <a href="http://academic.research.microsoft.com/Author/26096897">Hilda Tsai</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/84r8477ql4460637">view publication</a></span></p><p /><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 46, no. 1, pp. 189-191, 2010</cite>]]></description></item><item><title>The use of cell-delivered gene therapy for the treatment of HIV/AIDS</title><link>http://academic.research.microsoft.com/Publication/34424643</link><pubDate>Mon, 20 May 2013 07:43:53 GMT</pubDate><guid isPermaLink="false">34424643</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23626069">Geoff P. Symonds</a>, <a href="http://academic.research.microsoft.com/Author/27497795">Helen A. Johnstone</a>, <a href="http://academic.research.microsoft.com/Author/7713518">Michelle L. Millington</a>, <a href="http://academic.research.microsoft.com/Author/27453113">Maureen P. Boyd</a>, <a href="http://academic.research.microsoft.com/Author/27497796">Bryan P. Burke</a>, <a href="http://academic.research.microsoft.com/Author/27497797">Louis R. Breton</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/r1vr1t181j312252.pdf">view publication</a></span></p><p>HIV/AIDS is a disease that impairs immune function, primarily by decreasing T-lymphocyte count. Its progression can be contained by highly active antiretroviral therapy (HAART), but there are side effects that can be severe, and the development of resistance often forces the physician to modify the HAART regimen. There are no vaccines available for HIV. An alternative approach that ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 48, no. 1, pp. 84-98, 2010</cite>]]></description></item><item><title>Transcriptional target-based expression cloning of immunoregulatory molecules</title><link>http://academic.research.microsoft.com/Publication/34424614</link><pubDate>Mon, 20 May 2013 07:43:52 GMT</pubDate><guid isPermaLink="false">34424614</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/11895899">Rebecca L. Lamason</a>, <a href="http://academic.research.microsoft.com/Author/27497789">Stefanie M. Lew</a>, <a href="http://academic.research.microsoft.com/Author/23457190">Joel L. Pomerantz</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/content/d7232j422x33250n">view publication</a></span></p><p>Immunologic research has benefited tremendously from expression-cloning strategies designed to isolate genes responsible for a wide variety of immunomodulatory activities, including cytokines, receptors, signaling proteins, and transcription factors. Here, we discuss the use of expression-cloning strategies that have been modified to detect cDNAs that influence gene expression as assayed by a transcriptional reporter. We summarize our experience with ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 172-178, 2010</cite>]]></description></item><item><title>The prevalence of 30 ICD10 autoimmune diseases in Denmark</title><link>http://academic.research.microsoft.com/Publication/34424622</link><pubDate>Mon, 20 May 2013 07:43:51 GMT</pubDate><guid isPermaLink="false">34424622</guid><description><![CDATA[<p><a href="http://academic.research.microsoft.com/Author/23420728">William W. Eaton</a>, <a href="http://academic.research.microsoft.com/Author/5684945">Marianne G. Pedersen</a>, <a href="http://academic.research.microsoft.com/Author/11708531">Hjördís Ósk Atladóttir</a>, <a href="http://academic.research.microsoft.com/Author/27497791">Patricia E. Gregory</a>, <a href="http://academic.research.microsoft.com/Author/23539536">Noel R. Rose</a>, <a href="http://academic.research.microsoft.com/Author/4475469">Preben Bo Mortensen</a><span style="margin-left:20px" /><span style="margin-left:20px"><a href="http://www.springerlink.com/index/061588pnu0760675.pdf">view publication</a></span></p><p>Epidemiologic studies of autoimmune diseases have not considered them in the aggregate. The objective was to estimate the prevalence of 30 autoimmune diseases separately and in aggregate according to ICD-10 classification. The lifetime prevalence of the entire population of 5,506,574 persons alive in Denmark on October 31, 2006, was estimated by linking records of all visitors to ...</p><cite></cite><cite>Journal: <a href="http://academic.research.microsoft.com/Journal/6645">Immunologic Research - IMMUNOL RES</a>, vol. 47, no. 1, pp. 228-231, 2010</cite>]]></description></item></channel></rss>